TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27568069

Group type: EXPERIMENTAL
Intervention: Integrated PTSD and Smoking Treatment (IPST)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 80
Study: 24652692

Group type: EXPERIMENTAL
Intervention: 300,000 IU D₃
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 21955215

Group type: EXPERIMENTAL
Intervention: MVI ablation only (Group 1)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Cardioversion and repeat pulmonary vein (PV) isolation plus ablation of non-PV triggers (Group 2)
Number of subjects: 65
Study: 20513068

Group type: COMPARATOR
Intervention: Stem cell therapy
Number of subjects: 832
Study: 17668881

Group type: EXPERIMENTAL
Intervention: IL-6 high producer genotype
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: IL-6 low producer genotype
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: IL-6 high producer genotype in acute hepatitis C
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: IL-6 low producer genotype in acute hepatitis C
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: IL-6 high producer genotype in chronic hepatitis C
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: IL-6 low producer genotype in chronic hepatitis C
Number of subjects: 112
Study: 15608390

Group type: EXPERIMENTAL
Intervention: Gly/Trp and Trp/Trp genotypes
Number of subjects: 903

Group type: COMPARATOR
Intervention: Gly460Trp polymorphism
Number of subjects: 903
Study: 12234887

Group type: EXPERIMENTAL
Intervention: Entonox
Number of subjects: 20

Group type: COMPARATOR
Intervention: Air
Number of subjects: 20
Study: 9657656

Group type: EXPERIMENTAL
Intervention: Beta2 agonist (salbutamol) inhalation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7907871

Group type: EXPERIMENTAL
Intervention: Bunazosin retard (6 to 18 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2660284

Group type: EXPERIMENTAL
Intervention: Give-Up Smoking (GUS) kit and quit-smoking advice from their doctor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 29313415

Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR) plus psychostimulant
Number of subjects: 0
Study: 31340800

Group type: EXPERIMENTAL
Intervention: Calorie Counting (CC)
Number of subjects: 261

Group type: COMPARATOR
Intervention: MyPlate
Number of subjects: 261
Study: 28080169

Group type: EXPERIMENTAL
Intervention: FAMily‐Oriented Support (FAMOS), a home‐based psychosocial intervention delivered in six sessions.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 68
Study: 25147236

Group type: EXPERIMENTAL
Intervention: Valacyclovir 1000 mg
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 23534385

Group type: EXPERIMENTAL
Intervention: Dietary glycaemic load (GL)
Number of subjects: 1636

Group type: EXPERIMENTAL
Intervention: Dietary glycaemic index (GI)
Number of subjects: 1636
Study: 21777426

Group type: EXPERIMENTAL
Intervention: Group psychoeducation (21 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group peer support (21 sessions)
Number of subjects: 0
Study: 19689480

Group type: EXPERIMENTAL
Intervention: Intervention group (IG) with extra information and support to parents through group discussions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intervention group (IG)
Number of subjects: 60
Study: 16092313

Group type: EXPERIMENTAL
Intervention: Nimesulide (100mg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 67
Study: 10331397

Group type: EXPERIMENTAL
Intervention: Insulin infusion at rest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin infusion after exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postexercise recovery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin effects on glucose uptake and alanine transport
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin effects on phenylalanine, leucine, and lysine transport
Number of subjects: 0
Study: 8942881

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin ophthalmic solution 0.3%
Number of subjects: 324

Group type: COMPARATOR
Intervention: Standard therapy (fortified tobramycin 1.3%-cefazolin 5.0%)
Number of subjects: 324
Study: 1685323

Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 7079905

Group type: EXPERIMENTAL
Intervention: Intravenous iron plus folic acid
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intravenous iron‐dextran (Imferon; Fisons)
Number of subjects: 41
Study: 31003663

Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Breathing Awareness (BA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 29168012

Group type: EXPERIMENTAL
Intervention: Targeted RSV prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study: 27132150

Group type: EXPERIMENTAL
Intervention: Focal impulse and rotor modulation (FIRM) with irrigated radiofrequency (RF) ablation
Number of subjects: 27
Study: 24475275

Group type: EXPERIMENTAL
Intervention: Maraviroc intensification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-intensified regimen (Control)
Number of subjects: 0
Study: 22237735

Group type: EXPERIMENTAL
Intervention: Carperitide (0.02 g/kg/min, initiated at the start of surgery and continued for ≥5 days)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Carperitide
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (no carperitide)
Number of subjects: 88
Study: 19719746

Group type: EXPERIMENTAL
Intervention: Digoxin (0.01 mg/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 17611417

Group type: EXPERIMENTAL
Intervention: Gardasil immunization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV 18 L1 VLP immunization
Number of subjects: 0
Study: 16338245

Group type: EXPERIMENTAL
Intervention: fondaparinux
Number of subjects: 20000

Group type: COMPARATOR
Intervention: early angiography and intervention
Number of subjects: 20000
Study: 11978253

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study: 9535143

Group type: EXPERIMENTAL
Intervention: Low-alcohol beer (0.9% vol:vol)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Full-strength beer (5% vol:vol)
Number of subjects: 55
Study: 7635541

Group type: EXPERIMENTAL
Intervention: High-dose intravenous phenylephrine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous nitroprusside
Number of subjects: 8

Group type: COMPARATOR
Intervention: Finapres measurements during high-dose intravenous phenylephrine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Finapres measurements during intravenous nitroprusside
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Regional infusion of phenylephrine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Regional infusion of nitroprusside
Number of subjects: 8
Study: 2551565

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg)
Number of subjects: 20
Study: 31845837

Group type: EXPERIMENTAL
Intervention: Testosterone, dihydrotestosterone, and androstenedione
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone, 5alpha‐androstan‐3beta,17beta‐diol, androstenediol, and androsterone
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Extragonadal steroids
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Total androgen receptor transcriptional activity secondary to testosterone, dihydrotestosterone, and androstenedione
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Extragonadal androstenedione
Number of subjects: 335
Study: 30693610

Group type: EXPERIMENTAL
Intervention: Family activities for children with developmental delay
Number of subjects: 49

Group type: COMPARATOR
Intervention: Typically developing children
Number of subjects: 49
Study: 27592696

Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine (TIV)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control (hepatitis A vaccine)
Number of subjects: 124
Study: 25629819

Group type: EXPERIMENTAL
Intervention: Use of the mobile application
Number of subjects: 202
Study: 25697247

Group type: EXPERIMENTAL
Intervention: Physiological saline enemas with glycerol (0.8 ml glycerol + 3 ml saline or 1 ml glycerol + 5 ml saline)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Simulation (control group)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Physiological saline enemas with glycerol
Number of subjects: 101
Study: 22806274

Group type: EXPERIMENTAL
Intervention: Abatacept (two different dose regimens)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 20236380

Group type: EXPERIMENTAL
Intervention: Q-switched YAG laser treatment (Q-YAG 5 system, 1064 nm, Palomar Inc., Burlington, VT, USA); series of three treatments at 6-week intervals.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Punch biopsy excision; one treatment.
Number of subjects: 10
Study: 17996094

Group type: EXPERIMENTAL
Intervention: Laminectomy with dorsal fusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laminectomy without dorsal fusion
Number of subjects: 60
Study: 15791439

Group type: EXPERIMENTAL
Intervention: [99mTc]TRODAT‐1 SPECT binding in MSA patients
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: [99mTc]TRODAT‐1 SPECT binding in PD patients
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (age-matched controls)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Posterior putamen DVR in MSA patients
Number of subjects: 203
Study: 12088160

Group type: EXPERIMENTAL
Intervention: Nefazodone (mean final dose = 466 mg/day)
Number of subjects: 597

Group type: COMPARATOR
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (mean = 16.0 sessions)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Combination of nefazodone (mean dose = 460 mg/day) and CBASP (mean = 16.2 sessions)
Number of subjects: 597
Study: 9827437

Group type: EXPERIMENTAL
Intervention: Intrathecal administration of baclofen (initially 156 μg/24 hours, increased to 280 μg/24 hours)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal administration of baclofen
Number of subjects: 60
Study: 7896977

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study: 2559484

Group type: EXPERIMENTAL
Intervention: Fragmin (2,500 anti Xa units, subcutaneously, once daily for 5-9 days)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo (subcutaneously, once daily for 5-9 days)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Fragmin
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 206990

Group type: EXPERIMENTAL
Intervention: Follow-up outreach program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal treatment program
Number of subjects: 0
Study: 31429811

Group type: EXPERIMENTAL
Intervention: ondansetron (titrated up to 24 mg daily)
Number of subjects: 400

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 400
Study: 28214385

Group type: EXPERIMENTAL
Intervention: HIGH (6 doses of 250 IU/kg over two weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: COMB (HIGH dose plus nine micro-doses over three weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: HIGH-PLACEBO (saline control for HIGH group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: COMB-PLACEBO (saline control for COMB group)
Number of subjects: 32
Study: 25733628

Group type: EXPERIMENTAL
Intervention: Optimal models for month 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal models for month 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal models for month 3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percent weight loss alone
Number of subjects: 0
Study: 23211558

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based exercise training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Detraining period (24 weeks after exercise training)
Number of subjects: 0
Study: 22136019

Group type: EXPERIMENTAL
Intervention: Blood-pricking therapy combined with rehabilitation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Blood-pricking therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 96
Study: 19592054

Group type: EXPERIMENTAL
Intervention: L-arginine (6.4 g/d) for 6 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 17460405

Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment applied twice daily for 3 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0.12% betamethasone valerate ointment applied twice daily for 3 weeks
Number of subjects: 21
Study: 15544076

Group type: EXPERIMENTAL
Intervention: Fibrin glue combined with fibrinolysis inhibitor (aprotinin)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no fibrin sealant)
Number of subjects: 40
Study: 11913478

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg three times daily for 2 months)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 9152114

Group type: EXPERIMENTAL
Intervention: Vecuronium bromide (0.15 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancuronium bromide (0.1 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (0.15 mL/kg)
Number of subjects: 0
Study: 7959156

Group type: EXPERIMENTAL
Intervention: sulbactam/ampicillin 0.5/1.0 g, i.v. administered during surgery and repeated 6 hours later
Number of subjects: 100

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 100
Study: 3610469

Group type: EXPERIMENTAL
Intervention: Balloon technique for measuring stoma diameter
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Balloon technique for measuring pouch volume
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlation between stoma diameter and weight reduction
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pouch volume correlation with weight reduction
Number of subjects: 27
Study: 30084707

Group type: EXPERIMENTAL
Intervention: Metronidazole (63 patients)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Forzejeh (64 patients)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Comparison between Metronidazole and Forzejeh
Number of subjects: 127
Study: 26571184

Group type: EXPERIMENTAL
Intervention: Albumin and crystalloid solutions
Number of subjects: 995

Group type: COMPARATOR
Intervention: Crystalloid solutions alone
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T
Number of subjects: 995
Study: 25646891

Group type: EXPERIMENTAL
Intervention: 3D regimen of OBV, PTV/r, and DSV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol-containing contraceptives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progestin-only contraceptive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 17 of the 20 medications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemfibrozil, carbamazepine, or ethinyl estradiol-containing contraceptives
Number of subjects: 0
Study: 24134424

Group type: EXPERIMENTAL
Intervention: Decellularized dermal skin substitute (DCD) applied after hydrosurgical debridement and covered with negative pressure dressings for 1 week
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Decellularized dermal skin substitute (DCD)
Number of subjects: 20
Study: 20090562

Group type: EXPERIMENTAL
Intervention: Enzastaurin plus pemetrexed (250 mg two times per day; 500 mg/m intravenously on day 1 of 21-day cycles)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Pemetrexed (500 mg/m intravenously on day 1 of 21-day cycles)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Enzastaurin plus pemetrexed (combination arm)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Pemetrexed (pemetrexed arm)
Number of subjects: 160
Study: 18381986

Group type: EXPERIMENTAL
Intervention: Random drug testing conducted in school districts
Number of subjects: 1343

Group type: EXPERIMENTAL
Intervention: Random drug testing for athletes
Number of subjects: 1343

Group type: EXPERIMENTAL
Intervention: Random drug testing for students in extracurricular activities
Number of subjects: 1343

Group type: EXPERIMENTAL
Intervention: Random drug testing for all students
Number of subjects: 1343
Study: 16380824

Group type: EXPERIMENTAL
Intervention: Trasylol given during surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 40
Study: 15538040

Group type: EXPERIMENTAL
Intervention: Toremifene (TOR) 40 mg for 1 year
Number of subjects: 65

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg for 1 year
Number of subjects: 65

Group type: COMPARATOR
Intervention: Comparison of TOR vs TAM
Number of subjects: 65
Study: 11006188

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (Cetrorelix, 0.25 mg daily) during the late follicular phase
Number of subjects: 40

Group type: COMPARATOR
Intervention: No GnRH agonist or antagonist
Number of subjects: 40
Study: 9280175

Group type: EXPERIMENTAL
Intervention: Low-fat diet intervention group
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no specific counseling)
Number of subjects: 79
Study: 8315554

Group type: EXPERIMENTAL
Intervention: 3 mg p.o. (oral administration)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 1.5 mg i.m. (intramuscular administration)
Number of subjects: 25
Study: 3450908

Group type: EXPERIMENTAL
Intervention: Induced expectancy (high success potential)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no induced expectancy)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Instructor ratings of behavior and attitude
Number of subjects: 96
Study: 30138475

Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Training-Detraining
Number of subjects: 49
Study: 27317711

Group type: EXPERIMENTAL
Intervention: GlideScope®
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: C-MAC® with D-blade
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Head and neck position 'supine sniffing' vs 'supine neutral'
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Otolaryngologic or cardiac surgery vs general surgery
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Intubation performed by an attending anaesthetist vs a supervised resident
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Small mouth opening
Number of subjects: 1100
Study: 24604819

Group type: EXPERIMENTAL
Intervention: 1 dose of influenza A(H5N1) ISIV in LAIV-experienced subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2 doses of ISIV in LAIV-naive subjects
Number of subjects: 0
Study: 22841321

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation in PEEP/PRVC mode
Number of subjects: 92

Group type: COMPARATOR
Intervention: Preoperative oxygen supply via face mask or nasal tubes
Number of subjects: 92
Study: 20345840

Group type: EXPERIMENTAL
Intervention: Infant Behavioral Assessment and Intervention Program (IBAIP)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 112
Study: 18487998

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mononuclear cell therapy
Number of subjects: 3
Study: 16182911

Group type: EXPERIMENTAL
Intervention: Lingual flap retraction during mandibular third molar surgery
Number of subjects: 55

Group type: COMPARATOR
Intervention: No lingual flap retraction during mandibular third molar surgery
Number of subjects: 55
Study: 14686230

Group type: EXPERIMENTAL
Intervention: Valganciclovir 900 mg once daily
Number of subjects: 364

Group type: COMPARATOR
Intervention: Oral ganciclovir 1 g three times daily
Number of subjects: 364
Study: 9531875

Group type: EXPERIMENTAL
Intervention: FSH with LH (hMG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FSH alone
Number of subjects: 0
Study: 7787595

Group type: EXPERIMENTAL
Intervention: 50% sucrose
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 25% sucrose
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 12.5% sucrose
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 60
Study: 2690926

Group type: EXPERIMENTAL
Intervention: 1.0% apraclonidine
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (vehicle of para‐aminoclonidine)
Number of subjects: 99
Study: 31295205

Group type: EXPERIMENTAL
Intervention: Home treatment program combined with office-based canalith repositioning procedure (CRP)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Office-based canalith repositioning procedure (CRP) only
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both groups (Home treatment + CRP and CRP only)
Number of subjects: 106
Study: 28073018

Group type: EXPERIMENTAL
Intervention: Blm helicase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Improper crossover patterning
Number of subjects: 0
Study: 26841526

Group type: EXPERIMENTAL
Intervention: Comprehensive spa and health resort-based treatment with manual therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Balneotherapeutic treatment without manual therapy
Number of subjects: 110
Study: 25885729

Group type: EXPERIMENTAL
Intervention: 10 ml/kg crystalloid infusion (Group I)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 30 ml/kg crystalloid infusion (Group II)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Menstrual phase
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Proliferative phase
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Secretory phase
Number of subjects: 200